Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Basis of Presentation - Additional Information (Detail)

v3.7.0.1
Nature of Business and Basis of Presentation - Additional Information (Detail) - Achieve Life Science, Inc. [Member]
$ in Millions
Jan. 05, 2017
USD ($)
Right
shares
Jan. 04, 2017
Mar. 31, 2017
USD ($)
Nature of Business and Basis of Presentation [Line Items]      
Conversion of each outstanding share of Achieve common stock , shares converted | shares 4,242.8904    
Termination fee $ 0.5    
Termination fee upon breach of certain covenants regarding alternative transactions 1.0    
Third party expenses in connection with certain terminations $ 0.5    
Lock-up period with the execution of the merger agreement   180 days  
Number of contingent value rights to be issued for each share of common stock outstanding | Right 1    
Transaction costs associated with merger     $ 0.2
Contingent Value Rights [Member]      
Nature of Business and Basis of Presentation [Line Items]      
Combined company acquisition period results 5 years    
Aggregate consideration distributed to the holders, consideration received percent 80.00%    
OncoGenex Pharmaceuticals Equityholders [Member]      
Nature of Business and Basis of Presentation [Line Items]      
Percentage of ownership in combined company 25.00%    
Percentage of outstanding shares of capital stock held by certain officers and directors   1.20%  
Achieve Stockholders [Member]      
Nature of Business and Basis of Presentation [Line Items]      
Percentage of ownership in combined company 75.00%    
Percentage of outstanding shares of capital stock held by certain officers and directors   78.00%